


































The Australian Lung Foundation (ALF) is an independent, not-for profit
organisation, whose mission is to reduce the burden of lung disease in
Australia and promote lung health.
This economic statement was commissioned by the ALF as part of its
National COPD Program, and funded by an unrestricted grant to the authors.
The aims of the ALF’s COPD program are:
nn To raise the profile of COPD so it gets the attention it deserves
nn To improve COPD diagnosis and treatment
nn To educate the public and at-risk groups
nn To improve the quality of life for COPD patients and carers and ultimately
nn To reduce the human and economic cost of COPD.
The achievements of the ALF’s program since its inception in 2001 include:
nn Raised funds from non-government sources to develop COPD program
nn Published a case statement on COPD in Australia and New Zealand
nn Developed new national guidelines for the diagnosis and treatment of COPD
nn Committed to a best practice education program
nn Established a national patient support network and information service 
called LungNet
nn Initiated baseline research into prevalence and GP practice
nn Conducted research into patient needs and problems
nn Developed national standards for pulmonary rehabilitation.
nn Developed a theme for consumer communication encouraging a positive 
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nn COPD is costing the nation an
estimated $818 to $898 million
annually.  This is a conservative
estimate because it is based on
1993–94 figures extrapolated to the
Year 2001. The addition of hidden
costs could increase the estimate to
more than $1 billion per year. 
nn Prevalence estimates for COPD may
be well in excess of the most recent
AIHW figure of 300,000 (1996).
Two recent studies indicate that
COPD prevalence is in the range of
620,000 to 2.6 million cases.
nn More accurate prevalence figures
can only be obtained by a series of
integrated prevalence and costing
studies.
nn The current misdiagnosis,
misclassification and masking of the
diagnosis of COPD by other co-
morbid illnesses leads to a major
underestimate of the economic
burden of COPD.
nn The enormous burden on carers
represents a hidden/additional cost
not accounted for in the current
cost estimates.
nn Another hidden indirect cost is that
due to the management of
complications and co-morbidities
associated with COPD.
nn There are on average, 1,740 people
visiting a GP every day for COPD,
and 1,000 people occupying a
hospital bed. The average length of
stay in hospital is 7.2 days, at a
basic average cost of approximately
$3,700 per admission.
nn Hospital costs for COPD have
increased by almost 50% (CPI
adjusted) since 1993-94, and the
ageing population will ensure this
increase continues. 
nn Economic modelling, purely based
on GP and specialist consultations,
and using conservative prevalence
estimates, shows that there is a
considerable ‘unmet’ medical 
need due to the large number of
undiagnosed patients currently 
not receiving treatment.  There is
potential for these costs (and
others) to increase rapidly as the
prevalence increases and the
population ages.
nn A concerted effort is required to
improve the application of existing
COPD interventions (for which there
is evidence of effectiveness) and to
develop innovative strategies for
reducing the burden of COPD.
There is also a pressing need to
educate GP’s, allied health
professionals and consumers on
measures which can be taken to
































ACAM Australian Centre for Asthma Monitoring
AIHW Australian Institute of Health and Welfare
ALF The Australian Lung Foundation
AR-DRG Australian Refined Diagnosis Related Groups
CAL Chronic Airflow Limitation 
CAO Chronic Airflow Obstruction 
COAD Chronic Obstructive Airways Disease
COLD Chronic Obstructive Lung Disease
COPD Chronic Obstructive Pulmonary Disease
COPD-X Evidence based guideline for the management of COPD (The Australian
Lung Foundation and The Thoracic Society of Australia and New Zealand)
DALY Disability Adjusted Life Year
E65A AR-DRG code for Chronic Obstructive Airways Disease with catastrophic
or severe complications 
E65B AR-DRG code for Chronic Obstructive Airways Disease without
catastrophic or severe complications
E69A Bronchitis and Asthma Age>49 W CC
E69B Bronchitis and Asthma (Age<50 W CC) or (Age>49 W/O CC)
E69C Bronchitis and Asthma Age <50 W/O CC
GOLD Global Initiative for Chronic Obstructive Lung Disease
GP General Practitioner
































Chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) is also known as chronic obstructive
airways disease (COAD), chronic airflow limitation (CAL), chronic obstructive lung
disease (COLD) or chronic airflow obstruction (CAO) and includes the diseases chronic
bronchitis and emphysema. COPD is defined as a disease state characterised by
progressive development of airflow limitation that is not fully reversible.1 The distinction
of COPD from asthma is difficult in people over 40 years of age, both on clinical and
physiological grounds.
Cost
A cost is a use of resources, which therefore are not available 
to generate alternative benefits. 
There is considerable variation in the terminology of costs.  Drummond states that:2
nn Direct costs are the value of all goods and services consumed in order to prevent,
diagnose or treat an illness.
nn Direct costs to health services are those incurred through such agencies as
hospitals, medical practices and pharmacies, etc.
nn Direct costs to patients/family are those paid "out of pocket".
nn Indirect costs refer to lost (paid or unpaid) productive activity due to illness or
premature mortality.
nn Because pain and suffering do not represent tangible resources with alternative
beneficial uses, they are counted as burdens of disease rather than as costs.
nn Income transfers, such as through a pension or social security benefit, are not
regarded as costs.
The perspective taken in this statement is that of Australian society 
as a whole.
5





























1.1 What is COPD?
Chronic obstructive pulmonary disease (COPD) refers to a common group of largely
preventable long-term serious disorders, including chronic bronchitis and emphysema,
characterised by reduction in airflow that is not fully reversible. The airflow limitation is
progressive and associated with an abnormal inflammatory response of the lungs to
noxious particles or gases.1 COPD is a major cause of mortality, illness and a high level
of disability, particularly in the elderly, with patients suffering from cough, excessive
sputum and increasing shortness of breath. The disease develops gradually and
symptoms vary among individuals from mild shortness of breath to severe disabling
breathlessness on minimal exertion.
COPD is a major public health problem. As well as causing significant morbidity and
mortality, COPD is a risk factor for serious illness and death from a variety of other
diseases including pneumonia and influenza. COPD is also commonly associated with
diseases such as cancer and heart disease leading to a substantial economic burden on
individuals and society.3 Tobacco smoking including cigarette, pipe and cigar is the
most important risk factor for COPD. Smoking contributes about 85% of the risk of
developing COPD. The susceptibility of individuals to developing COPD from tobacco
smoking is variable.4 While smoking is the major risk factor, the reason why fewer than
20% of smokers develop significant airways disease is unknown. Other documented
risk factors for COPD include exposure to occupational dusts and chemicals, indoor
and outdoor air pollution, passive smoking, chest and viral infections and predisposing
factors such as genetic variations.5 With currently available therapies, the underlying
cellular pathology of COPD is irreversible, but its progression may be slowed if risk
factor exposure is reduced. 
The burden of disease through mortality, disability, impairment, illness and injury can
be quantified in terms of a Disability Adjusted Life Year (DALY).6 The measurement of
DALYs combines both the years of life lost due to premature mortality and the years lost
to disability. In 1996, the Australian Institute of Health and Welfare (AIHW) estimated
the burden of disease and injury in Australia based on the DALY and confirmed the
morbidity of chronic lung disease. COPD was rated the third leading cause of disease
burden behind ischaemic heart disease and stroke and responsible for 3.7% of the total
disease burden in Australia.6 The National Health Priority Areas diabetes mellitus and
asthma were rated seventh and ninth causes of disease burden respectively.
Clearly, COPD represents an enormous problem for Australia and the Australian General
Practitioner (GP), who is primarily responsible for treating this chronic condition, and
warrants priority as an area for primary health care research, evaluation and
development. The disease impacts not only on patients but also on carers and the
community as a whole. However, there is a low awareness and a poor profile of the
disease in the community. Its causal links with smoking have tended to create stigma
with the perception that COPD is a self-inflicted irreversible disease.7 Prioritising COPD
as a National Health Priority Area should lead to an increase in collaboration,
monitoring and research. A concerted effort is required to improve the application of
existing COPD interventions (for which there is evidence of effectiveness) and to
develop innovative strategies for reducing the future burden of COPD. There is also a
pressing need to educate GP’s, allied health professionals and consumers on measures































The current disease burden of COPD represents a fundamental problem for Australia
and most other nations and demands immediate attention. Chronic lower respiratory
tract disease is the fourth highest cause of death in Australia behind cancer, ischaemic
heart disease and stroke and accounted for 5,962 deaths in 2000 or 5% of all deaths.8
While other diseases have shown a decline in mortality over recent years, COPD has
been reported to be the only leading cause of death increasing in prevalence.9
It is projected to be the third leading cause of death by the year 2020.10 In Australia,
age-specific mortality from COPD, although decreasing in males since the 1970s, has
been steadily increasing in females with Australian female COPD mortality predicted to
overtake male mortality within the next five years.11,12 Mortality from COPD relative to
that of the normal population appears to be worse for Australian patients than for
some European COPD patients.13 COPD affects mainly older people with death rates
increasing significantly for people from 60 years of age.12 On average, people with
COPD die 7 to 8  years earlier than the age-adjusted average rate of death.14
The actual number of people suffering from COPD in Australia is not known because
substantial differences are apparent in estimates based either on self-report of
symptoms or self-report of a medical diagnosis or on the measurement of lung
function by spirometry where different cut off values are used. The measured
prevalence of COPD depends on several factors as well as diagnostic criteria, such as
concurrent medical conditions, the need to make age adjustments to survey data, and
adjustments for changing revisions to the International Classifications of Diseases (ICD)
codes.9 Hence, there are currently several widely different prevalence estimates for
COPD in Australia. 
nn The AIHW estimated there were almost 300,000 persons with COPD in 1996 with
more than 20,000 new cases annually.6 Extrapolating this data to the year 2000
gives an estimate of 380,000 person with COPD. 
nn Recently, 12.4% of a random sample of adults aged between 45-70 responding to
a postal survey conducted by the Monash Medical School and the Alfred Hospital
self-reported chronic bronchitis or emphysema.15 Extrapolating this point
prevalence to the total Australian population aged between 45-70 years gives an
estimated 620,414 people with COPD in Australia in this age group based on the
population at 30 June 2000.
nn A prevalence estimation model has been applied to estimate the prevalence of
COPD in seven Asia-Pacific Countries including Australia. The model produced an
estimated prevalence of COPD of 6.3% for the twelve countries. The report goes
on to estimate the number of moderate to severe cases of COPD in Australia at
4.7% of the total population aged greater than 30 years (558,000 cases) in the
year 2000.16
nn The Busselton study (1990) estimated that chronic airflow limitation, measured by
spirometry during seven population health surveys conducted between 1966 and
1984, occurred in 24% of men and 18% of women who were regular smokers
and 5% of male and 8% of female non-smokers.17 
nn A recent study used spirometry to estimate the prevalence of COPD in a random
population of 2,500 South Australian adults aged over 18 years.18 The prevalence
of mild, moderate and severe COPD was estimated to be 24.1%. The prevalence
varied by area with the highest rates reaching 27%. Extrapolating the prevalence
from this study to the Australian population aged between 45 - 70 years at 
30 June 2000 would give an estimated prevalence of 1.2 million persons with
COPD. Extrapolation to the Australian population aged over 30 years would give






























COPD is usually found in association with comorbidities due to several
reasons:
1. Tobacco smoking causes lung cancer, ischaemic heart disease, stroke and a range 
of other conditions as well as COPD.19
2. COPD has effects on nutritional status, muscle wasting and depression.5
3. COPD increases the susceptibility of the lungs to infection, such as pneumonia or
influenza.19
4. The pathological changes due to COPD may lead, in turn, to failure of the right side
of the heart and thence further pathology.20
5. Smoking tends to cluster with other unhealthy behaviours such as excessive alcohol
consumption, a diet high in saturated fats and low levels of exercise.21 Thus COPD is
found in association with diabetes.
6. A higher than expected proportion of people with COPD also have obstructive sleep
apnoea.22
7. Treatment of COPD with corticosteroids has side-effects such as osteoporosis.23
8. Since COPD usually requires many years of exposure to tobacco smoke, it tends to
be associated with other diseases that are more prevalent in old age.
Prevalence in indigenous Australians
Chronic lung disease is a major cause of mortality and morbidity in indigenous
Australians. They die from COPD at a rate 10 times greater than non-indigenous
Australians.24 High smoking rates (56.1% males and 48.3% females)25 and high rates of
infectious disease amongst indigenous Australians are likely to continue to contribute to
this high mortality rate for many years in the future. A recent study of 244 indigenous
Australians in the Northern Territory reported that COPD was generally unrecognised
by health providers only being documented in the health record of 8% of those with
COPD.24 Chronic respiratory symptoms of chronic bronchitis and recent wheeze were
poor predictors of airflow obstruction giving support for community-wide spirometry
screening in communities with a high prevalence of respiratory disease and tobacco
use.24
1.3 Treatment and management
COPD has no cure and treatment options are still relatively limited. Smoking cessation is
the single most effective, cost-effective means to reduce the risk of developing COPD
and to slow the progression of airflow limitation.1 No other therapy has been found to
modify the natural history of COPD. Current management of COPD is aimed at
relieving symptoms, controlling exacerbations and improving exercise tolerance.
Management includes both pharmacologic and non-pharmacologic therapies including
pulmonary rehabilitation. A major initiative of the Australian Lung Foundation (ALF) has
been to develop standards to facilitate establishment of pulmonary rehabilitation
programs, which are currently under-supported in Australia. Management of COPD 
is guided by the severity of the disease as recommended by the draft ALF COPD-X
































nn  Avoidance of risk factors(s)
nn  Influenza vaccination
nn  Intermittent bronchodilator
nn  Intermittent or regular
bronchodilators
nn  Combination bronchodilator 
may be considered
nn  Rehabilitation
nn  Inhaled glucocorticoids 
if significant symptoms and 
lung function response
nn  Regular combination 
bronchodilator 
nn  Inhaled glucocorticoids
if significant symptoms and 
lung function response or if
repeated exacerbations
nn  Treatment of complications
nn  Rehabilitation
nn  Long-term oxygen therapy
nn  Consider surgical treatments
Characteristics
nn  FEV1/FVC <70%
nn  FEV1 >80% predicted
nn  With or without chronic
symptoms
nn  FEV1/FVC <70%
nn  30% < FEV1 <80% predicted 
(2A:50% <FEV1 <80%, 
2B:30% <FEV1 <50% 
predicted)
nn  With or without chronic
symptoms
nn  FEV1 /FVC <70%
nn  FEV1 <30% predicted or 
FEV1 <50% predicted plus
respiratory failure or clinical 
signs of right heart failure
Table 1. Therapy at each stage of COPD










nn Bronchodilators; help to open up narrowed airways.
nn Glucocorticoids; reduce inflammation in patients with severe COPD 
and repeated exacerbations. 
nn Vaccines; Vaccines for influenza and pneumonia can reduce serious illness 
and death in COPD patients.
nn Antibiotics; For treatment of acute infections.
nn Mucolytic agents; Overall benefits in COPD patients tend to be very small.
nn Antitussives; Regular use is contraindicated in COPD.
nn Respiratory stimulants; Not recommended for regular use.
Non-pharmacologic agents:
nn Rehabilitation; Programs include exercise training and education including
nutritional advice, and aim to reduce symptoms, improve quality if life, increase
capacity to self-monitor with confidence, increase exercise capacity and decrease
depression.
nn Oxygen therapy; Long-term oxygen therapy has been shown to improve survival
in hypoxaemic COPD patients if used for more than 15 hours per day.20,26 
nn Surgery; bullectomy and lung transplantation considered in carefully selected
patients. 
nn Mechanical ventilation; There is little evidence that mechanical ventilation has 





























1.4 Impact of treatment
The prediction that COPD will rise to be the third leading cause of death worldwide 
by the year 2020 has enormous implications for economic management of healthcare.
Current prevalence estimates are likely to be under-estimates, as the disease is often not
diagnosed until late in its course when lifestyle is significantly impaired. In Australia,
with an aging population and the improvement in treating other chronic disease, the
burden of COPD is likely to continue to increase for some years even if the prevalence
of cigarette smoking continues to decrease and most of this increase will be in women. 
In 2000-01 COPD (AR-DRG codes E65A and E65B) accounted for:27
nn 50,779 separations (0.85% all separations for public and private hospitals).
nn 16.9% of all separations for the respiratory system. 
nn 366,516 bed days with an average length of stay of 7.2 days. 
In addition in 2000-01 it is estimated that there were:28,29
nn 635,782 (0.7%) visits to a GP for COPD.
The number of hospital separations for COPD (AR-DRG E65A, E65B) is increasing
annually (Figure 1).27 Males have more hospital admissions for COPD than females. 
The rate of hospitalisation has increased by 11.1% for males and 13.2% for females
from 1997-8 to 2000-01. In contrast the rate of hospitalisation for bronchitis and
asthma (E69A, E69B, E69C) has decreased by 7.9% over the same period.
Figure 1. Hospital separations for COPD and bronchitis/asthma
1997-98 to 2000-01 in Australia 
The number of hospital bed days for COPD (AR-DRG E65A, E65B) has increased with
the number of hospitalisations (Figure 2). The number of bed days increased by 6.6%
for COPD or 2% annually and decreased by 18.9% (over 6% annually) for bronchitis
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Figure 2. Hospital bed days for COPD and bronchitis/asthma









COPD Bronchitis and asthma
1998-99 1999-00 2000-01
Source: National Hospital Morbidity Database





























The cost burden associated with COPD is substantial and rising with increasing
prevalence of the disease (ALF estimated cost of COPD in 1998; $800 million per
annum).30 COPD affects patients, caregivers and society as a whole. For persons
suffering from the disease it affects not only medical resource use but also health status,
daily life and activities. Lung diseases, and COPD in particular, also affect work
productivity, being among the three main causes of lost workdays.31 However,
estimating the economic burden of COPD is difficult, as there is little data on the
burden of illness imposed on society.31 In addition, misdiagnosis, misclassification 
and masking of the diagnosis by other co-morbid illnesses leads to a major
underestimate of the economic burden. 
The costs attributable to COPD are not uniform across patients but vary according to
health status, gender, and the amount of comorbid illness. In a recent study of costs
incurred by persons with COPD in the US approximately 20% of persons with COPD
accounted for about 74% of total expenditure.31
2.1 Direct costs
Direct costs are the value of all goods and services consumed in order to prevent,
diagnose and treat illness. The AIHW employed a prevalence-based approach for
estimating the direct cost of health services in a major study of health system costs 
of diseases and injury in Australia for the 1993-94 financial year.32 The methodology
used is described in detail according to the major chapter groupings of the Ninth
Revision (now superceded) of the International Classification of Diseases (ICD-9).33 
The estimations were based on the estimated resident Australian population by age
and sex at 30 June 1994. The AIHW focused on direct costs because of the controversy
and debate surrounding the calculation of indirect costs. The information on costs was
estimated by detailed health sector for a given disease group defined in terms of a
chapter of ICD-9.
In 1993-94 the AIHW estimated the health cost for all lung diseases to be $2.5 billion
or 8% of the total health system costs. Lung diseases were the sixth most costly disease
group.32 Hospital cost was the largest contributor to health care costs for all lung
diseases at $833 million dollars. This estimate included a cost to public hospitals 
($527 million), private hospitals ($128 million) and for non-inpatients ($177 million).
Total pharmaceutical costs including both prescription and over the counter
medications were estimated to be $733 million dollars.
The estimated Consumer Price Index (CPI), adjusted to 2001, costs for all lung diseases
for a selected group of healthcare sectors (public hospitals, private hospitals and a
combined cost for prescribed pharmaceuticals (Pharmaceutical Benefits Schemes (PBS)
and Repatriation Pharmaceutical Benefits Schemes (RPBS)) from 1993-94 to 2000-01 
are shown in Figure 3. CPI adjusted costs attributed to all lung diseases have increased
during this time interval by 20% for public hospitals, 16% for private hospitals and 































Figure 3. Estimated (CPI adjusted to 2001) annual cost 
($ million) for selected health care sectors for lung disease
Source: Australian Hospital Statistics 1995-96 and 2000-01
HIC Annual Reports Pharmaceutical and Repatriation Pharmaceutical Benefits
Schemes Statistical Tables
The AIHW estimated that the cost for COPD alone in 1993-94 was $300 million,
almost three times as much as that for lung cancer.12 Hospitalisation accounted for the
major proportion of costs for COPD ($112 million) followed by pharmaceutical costs
($66 million) as shown in Figure 4. The hospitalisation costs for COPD represented
13.4% costs of hospitalisation for all respiratory disease. Most COPD hospitalisations
occur in the public sector.
Figure 4. Estimated cost of COPD by health sector 1993-94






























































Comparison of the 1993-94 estimated cost of COPD with the cost of each of the six
National Health Priority Areas is shown in Figure 5.36 The cost of COPD was estimated
at approximately one half the cost of asthma.
Figure 5. Health system costs for the National Health Priority
Areas and COPD, 1993-94 
Source: Australia’s Health 2002
In 2000-01 the AIHW estimated the public and private hospital cost for COPD (AR-DRG
E65A and E65B) to be $188 million.35 This represents an increase of 46% from the
1993-94 CPI adjusted estimate of hospital costs for COPD. The 1993-94 hospital cost
also included a non-inpatient cost, which is not included in the $188 million hospital
cost estimate for 2000-01. Therefore, the 2000-01 estimated hospital cost for COPD is
an underestimate in comparison with the CPI adjusted 1993-94 hospital cost. The
hospital cost for COPD was the highest hospital cost of any respiratory disease and
almost double the estimated hospital cost for asthma of $95 million in 2000-01. The
rate of increase in costs for COPD has exceeded the rate for total lung disease probably
due to the ageing population and the increasing mortality and morbidity associated
with this disease. 
A lack of reliable current prevalence information plus the contribution of comorbid
illness to the overall burden of disease makes the task of estimating the current cost of
COPD in Australia extremely difficult. The AIHW estimated direct costs by taking known
aggregate expenditures on health care and apportioning these to disease categories
using known hospital morbidity data, casemix data, the 1990-91 GP survey and the
1989-90 Australian Bureau of Statistics (ABS) and National Health Survey.32 The direct
costs calculated did not include costs for ambulance services, health promotion and
disease prevention. To gain an insight into the current cost of COPD requires a repeat
of the surveys undertaken previously with similar methodology employed but is
dependent on reliable prevalence estimates. As a result, this brief economic statement
can only arrive at a cost estimate for COPD in 2000-01 by extrapolation of the 1993-94
AIHW cost estimates of the health sectors of COPD taking into account currently
available data. 
Direct cost estimates for COPD for 2000-01 and 1993-94 are given in Table 2. The
hospital cost for COPD (E65A and E65B) for 2000-01 was obtained from the AIHW
National hospital morbidity database and assumed to represent 37.3% direct costs for
COPD as estimated in 1993-94 by AIHW. The costs for the other health sectors were
then calculated assuming pharmaceuticals represented 22%, medical costs 20.3% and







































Table 2. Estimated direct costs to the health system of COPD 
*The estimated total direct cost of COPD of $503 million does not include the direct
hospital costs of non-inpatients, nor the direct costs of related diseases and conditions
associated with COPD and so represents an underestimate of the true health system
impact of the disease.
Source: AIHW. Chronic diseases and associated risk factors in Australia, 2001
AIHW Australian hospital statistics 2000-01
2.3 Indirect costs
Indirect costs refer to lost productive activity due to the illness or premature death of
the patient but can also include carer burden and opportunity cost to the carer and a
cost to the community. Their inclusion in estimating the cost of illness remains
controversial. 
It is very difficult to estimate indirect costs for COPD. However, based on overseas
experience, indirect costs may be substantial due to the significant degree of disability
of COPD patients.37 COPD patients experience progressive disability associated with the
decline in lung function. The majority of people are incapable of productive work
within a few years of diagnosis of COPD. 
The indirect cost to carers has not been measured in Australia. With the increasing
prevalence of COPD in females and the fact that many of these women are widowed,
the burden of care is falling increasingly on the extended family or community
services. 
2.4 Total cost
A US estimate attributed 56% of the total cost burden of COPD to direct costs and
44% to indirect costs.37 Indirect costs included estimated costs for lost wages, lost
fringe benefits and lost production. Another US estimate attributed 61.5% cost of
COPD to direct costs and 38.5% cost to indirect costs (indirect morbidity costs and
costs related to premature mortality).3 Applying these estimates to COPD would give
an estimated indirect cost for COPD in Australia of from $315-$395 million in the year
2000-01.
Combining the estimates for direct and indirect costs provides a total cost estimate for
































































In 1998, the ALF, employing the method of Hensley and Saunders38 estimated the total
direct and indirect cost of COPD in Australia of approximately $800 million.30 The
indirect costs were estimated as productivity or earnings losses that would be expected
assuming that a patient experienced no significant disability at the time of onset or
diagnosis and complete withdrawal from all forms of productive activity seven and a
half years later. This estimate is similar to the estimates in Table 3 above. The costs of
the comorbidities associated with COPD are hidden costs and are not included in these
cost estimates
The current health system costs are for late-stage disease. Earlier disease diagnosis
should lead to better secondary prevention (smoking cessation, physical exercise)
which is likely to delay or reduce the future cost burden of COPD.
2.5 Home oxygen therapy
An example of how costs of individual items can impact on the cost of illness is the
supply of home oxygen therapy to patients with COPD in Australia. Long-term home
oxygen therapy is one of the more costly interventions for COPD but is probably 
cost-effective because of its positive impact on mortality rates.39
In South Australia (SA), the cost of home oxygen therapy is covered primarily by 
site-specific grants provided to public hospitals by the state government Department 
of Human Services. Veterans receive their home oxygen therapy through the
Department of Veterans Affairs while country hospitals provide home oxygen therapy
for rural patients. 
Most tertiary referral public hospitals in Southern Adelaide provide home oxygen
therapy to patients assessed by the Respiratory Units as requiring this therapy. The cost
of the provision of oxygen therapy at one such hospital has continued to increase, 
in spite of the introduction of cost saving strategies such as oxygen concentrators, 
in line with the ever-increasing number of patients requiring this therapy. Figure 6
shows the cost increases associated with the supply and maintenance of home oxygen
therapy by this hospital from 1984-85 to 1999-2000.
16


















































Figure 6. CPI adjusted annual cost, budget allocation and
number of prescriptions for home oxygen therapy provided 
by an Australian tertiary referral hospital
We have estimated there were approximately 111 patients on home oxygen therapy
per 100,000 population in SA in the year 2001. Extrapolating this to the 2001
Australian population gives an estimated 21,700 patients on home oxygen therapy.
The cost of providing home oxygen therapy in SA in the year 2001 was approximately
$1,400 per patient. On the basis of this, an estimated annual Australian cost of 
$30.4 million can be calculated for the provision of home oxygen therapy. Most of 





























































































The burden associated with COPD includes both significant disability and premature
death and increases with increasing age. In 1996, COPD was the largest contributor to
the burden of lung diseases, more than 4 times the burden of other chronic respiratory
diseases and conditions.40
3.1 ‘Unmet’ need
COPD has long received less than due recognition by health professionals in contrast to
the enormous effort that has been made both Nationally and Internationally to improve
asthma management.7 The recent study by Abramson reported that less than 20% of
participants who were found, on laboratory tests, to have COPD had been diagnosed
by a doctor.15 These undiagnosed patients will impact on healthcare provision in future
years.
The Tan study estimated the prevalence of moderate to severe COPD as 558,000
cases.16 Modeling has been performed to obtain a cost estimate for the provision of
medical (GP and Respiratory specialist consultations) to COPD patients based on these
prevalence figures as shown in Figure 7. The unit cost of a GP encounter was set at
$27.00, the fee for Item 23 of the Medicare Benefits Schedule for the year 2000. The
unit cost of respiratory physicians consultations were similarly obtained from the
Medicare Benefits Schedule for the year 2000 - Item number 110; $119.35 consultant
physician referred consultation, and Item 116; $59.75 for subsequent consultant
physician review consultations.
Figure 7. Estimated annual cost ($ million) of GP and specialist
respiratory physician consultations for 558,000 moderate to
severe COPD patients in Australia
18
3 The Burden of Disease 













consultations GP 1 
consultation
GP 2 





































From Figure 7 it can be seen that the provision of medical services alone to an estimated
558,000 patients with moderate or severe COPD could cost from $82 million for 1 GP
visit and 1 Specialist visit annually for each patient to $190 million if each patient were to
have 6 GP visits, 1 specialist consultation and 1 specialist review per year. This number of
medical consultations for moderate or severe COPD patients is not unrealistic. The
control group patients included in a recent GPEP study of home based care of patients
with COPD, had a mean of 4.58 GP consultations during the 9 months of the study,
equivalent to 6 GP consultations annually.41
The estimated $102 million cost for medical services for COPD (Table 2) would allow
only 2 GP consultations and 1 specialist consultation for each COPD patient with
moderate or severe disease in the year 2000. The modeling demonstrates the large ‘unmet’
medical need of patients with COPD in Australia and the potential for future costs to
escalate rapidly as the prevalence of the disease increases and the population ages.
With limited treatment options and a high mortality rate there is also a great ‘unmet’
need to develop new improved therapies for COPD. Research needs to be focused on
gaining a better understanding of the disease at a cellular and molecular level, more
accurate methods for detection and screening and new therapies that not only improve
symptoms but which can stop disease progression and hopefully provide a cure for COPD.42
3.2 Reduced quality of life
COPD patients often experience a marked reduction in quality of life.43 Severe
decrements in health-related quality of life (HRQoL) as measured by validated instruments
have been found for COPD patients in comparison with age-matched normal
populations.44 The decrements occur in most dimensions of HRQoL including physical
and social function, mobility, energy, sleep and emotional functioning. HRQoL scores
have been found to be similar to those of patients suffering congestive heart failure or
myocardial infarction.43 COPD patients and their carers may also experience considerable
depression and anxiety in relation to the illness and its associated disabilities, that are
difficult to quanitfy.17
In 1998, the Respiratory Unit of a South Australian public hospital conducted a series 
of interviews with COPD inpatients their carers and their GPs. A trained, experienced,
respiratory clinical nurse was recruited by the Respiratory Unit to interview COPD 
in-patients, carers and their GPs for their views on the patient’s reasons for
admission/readmission to hospital, the patient's knowledge of their illness, medications,
social supports and quality of life. A total of 87 (29 males; 58 females) in-patients (plus
10 re-interviews), 12 GPs and 23 carers were interviewed. The mean age of the patients
interviewed was 71.6 years (range 50-89).
A selection of individual patient responses representative of the common themes 
for many of the patients follows. The responses highlight patient perceptions and
problems associated with their chronic illness and its comorbidities and the feelings 































"…I mean I am on 30 pills a day now, I can’t keep up 30 pills a day, 
that is ridiculous."
"The locum came down and when he looked at the listing of medication 
I have got he said I don’t think there is anything left. The best thing is to
take her to hospital."
"…I was unwell for probably a few days before I went to the doctors …
I knew that there was probably not a lot that they could do for me… 
so I just kept going until I just couldn’t go on any further."
"I never want to go home after I have been in here (hospital) because 
I feel so safe."
"Well I was here (in hospital) fourteen times and I had a different complaint
every time."
"The thing is when you are on your own you have a tendency to panic….
and that only makes the problem worse."
"…it is very difficult because no sooner do we apply for help than they 
take it off our pension. Do you know what I mean? We can’t afford it …
We can’t afford help you know but yes, we do need help."
Carers' responses
"I have not been well myself, I only came out of hospital about four weeks
ago."
"…he is a very frightened man as well, he needs constant reassurance."
GP' responses
"…I have experience in many different fields, but I am always a little unsure






























The burden of disease and the costs to society of COPD are not inevitable and fixed.
However, a concerted effort is required to improve the application of existing COPD
interventions (for which there is evidence of effectiveness) and to develop innovative
strategies for reducing the burden of COPD. There is also a pressing need to educate
GP’s, allied health professionals and consumers on measures which can be taken to
improve the health and economic outcomes for COPD. 
Several strategies have been introduced in an attempt to reduce the disease burden
associated with COPD. Increased basic and applied research effort is required to
investigate the cost-effectiveness and long-term effects on morbidity and mortality of
many of these interventions and to develop new strategies and new therapies for
improved management.
Examples of strategies to reduce the burden of COPD include:
nn Prevention of smoking 
It is estimated that 90% of the health care costs of COPD in men and 80% in women
are attributable to smoking.45 Smoking prevention/cessation is the single most
important intervention to reduce the escalating cost of COPD. The rate of decline of
lung function is accelerated by smoking and smoking cessation slows this rate of
decline in lung function in patients with COPD.46 Primary prevention has led to a
progressive reduction in the number of Australian adults currently smoking, but little
attention has been given to secondary prevention i.e., helping smokers with proven
disease to quit. A recent Australian review of the pharmacotherapy of smoking
cessation found that all forms of nicotine replacement therapy and bupropion were
effective as part of a strategy to promote smoking cessation. More intense levels of
patient support are beneficial in facilitating the likelihood of quitting.46
nn Vaccination
Along with smoking cessation the only other proven cost-effective therapy for COPD 
is vaccination to prevent influenza infection. Influenza vaccination can reduce serious
illness and death in COPD patients.1 A recent study in the Netherlands found that
immunisation of elderly patients with chronic lung disease against influenza was
effective and cost-saving.47
nn Pulmonary rehabilitation
Pulmonary rehabilitation is a multidisciplinary intervention which aims to reduce
symptoms, improve quality of life and increase mobility and physical endurance. 
The programs generally include exercise training, education, and nutrition counselling.
COPD patients have been shown to benefit from pulmonary rehabilitation with
improvement in exercise tolerance and fatigue.48 The long-term cost-effectiveness of
pulmonary rehabilitation and the effects on mortality are still unknown in Australia
although cost-effectiveness has been shown in the UK.49
nn Home based care 
The high hospitalisation costs incurred by patients with COPD have encouraged the
development of home-based care treatment programs for COPD patients in Australia 
in recent years. A recent trial of home based care versus hospital care for acute COPD
reported that an acute care at home scheme could substitute for usual hospital care
for some patients potentially freeing up resources. However significant comorbidities
were a limiting factor.50
4 Strategies to Reduce 





























nn COPD has become an epidemic. Disease due to COPD is one of the largest public
health problems facing our society. In the past COPD has long received less than
due recognition by health professionals in comparison with other lung diseases
such as asthma. Treatment options for patients are still relatively limited and people
with COPD are still experiencing poor quality of life.
nn There is currently no coordinated data collection for COPD in Australia. The
Australian Centre for Asthma Monitoring (ACAM) has been established to develop 
a systematic approach to the surveillance of asthma across Australia, to monitor
disease levels, burden and trends and to identify the potential for improved
prevention and management of the disease. Such a coordinated systematic
approach is required for COPD and would enable the refinement of uniform
definitions and indicators of disease for monitoring.
nn There is an urgent requirement for reliable prevalence data for COPD for the
prediction of current and future health care needs and to monitor trends. Only two
Australian prevalence studies based on population samples have been performed 
in recent years.  One study found that 12.4% of the population aged between 
45 and 70 years of age self-reported COPD, equivalent to 620,000 cases.  The
other study estimated the prevalence of mild, moderate and severe COPD to be
24.1% which if extrapolated to the Australian population aged 45-70 years would
be equivalent to 1.2 million cases or to the Australian population over 30 years 
2.6 million cases.
nn COPD presents a major burden to the health care system. The cost associated with
COPD is large with hospitalisation the greatest contributor to overall health care
cost. Extrapolation from the costs estimated by the AIHW in 1993-94 gives an
estimated cost of $818-898 million for COPD in the year 2000-01. A study similar 
to that performed by the AIHW in 1993-94 is required to obtain accurate estimates
of costs. Such a study is dependent on reliable prevalence estimates.
nn There is a large ‘unmet’ clinical need for more effective therapies and better
outcomes for people with COPD. Recent studies such as the international GOLD
study and the work of the ALF have resulted in the formulation of guidelines for 
the management of COPD. The cost-effectiveness of these guidelines needs to be
studied from the point of introduction to guide future resource allocation 
decision-making.
nn An economic study needs to be applied to current interventions to provide some
indication of the optimal mix that will provide the greatest improvement in health
outcomes for Australian COPD patients. This proposed study would provide a rich
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